64095-60-9

Usage

Uses

Used in Pharmaceutical Industry:
LONGISTYLINE A is used as an anti-inflammatory agent for its ability to inhibit the production of nitric oxide and prostaglandin E2, which are crucial in inflammatory processes.
Used in Pain Management:
LONGISTYLINE A is used as an analgesic for its antinociceptive properties, making it a potential treatment for pain-related disorders.
Used in Oxidative Stress Management:
LONGISTYLINE A is used as an antioxidant for its demonstrated activity in combating oxidative stress, which is implicated in various pathological conditions.
Used in Research and Development:
LONGISTYLINE A is used as a subject of pharmacological research for its promising properties, indicating potential for further development in therapeutic applications.

Upstream product

• 115-18-4 2-methyl-3-buten-2-ol 
• 35302-70-6 3-methoxy-5-[(E)-2-phenylvinyl]phenol 
• 6110-37-8 methyl 2,4-dimethoxy-6-methylbenzoate 
• 70719-50-5 2-bromomethyl-4,6-dimethoxy-benzoic acid methyl ester 
• 1258410-99-9 (E)-2,4-dimethoxy-6-styrylbenzoic acid methyl ester 
• 1363155-62-7 (E)-methyl 2-hydroxy-4-methoxy-3-(3-methylbut-2-en-1-yl)-6-styrylbenzoate 
• 870-63-3 prenyl bromide 
• 100-52-7 benzaldehyde 

Relevant academic research and scientific papers

Design and Synthesis of Cajanine Analogues against Hepatitis C Virus through Down-Regulating Host Chondroitin Sulfate N-Acetylgalactosaminyltransferase 1

There still remains a need to develop new anti-HCV agents with distinct mechanism of action (MOA) due to the occurrence of resistance to direct-acting antiviral agents (DAAs). Cajanine, a stilbenic component isolated from Cajanus cajan L., was identified as a potent HCV inhibitor by phenotypic screening in this work (EC50 = 3.17 ± 0.75 μM). The intensive structure optimization provided significant insights into the structure-activity relationships. Furthermore, the MOA study revealed that cajanine inhibited HCV replications via down-regulating a cellular protein chondroitin sulfate N-acetylgalactosaminyltransferase 1. In consistency with this host-targeting mechanism, cajanine showed the similar magnitude of inhibitory activity against both drug-resistant and wild-type HCV and synergistically inhibited HCV replication with approved DAAs. Taken together, our study not only presented cajanine derivatives as a novel class of anti-HCV agents but also discovered a promising anti-HCV target to combat drug resistance.

Diarylvinylene similar structure compound and its preparation method and application

The invention discloses a group of diarylethene structure similar compounds as well as a preparation method and application thereof. The provided compounds have a structure of a general formula I. Moreover, the invention further provides medicinal compositions containing the compounds serving as active ingredients. Researches discover that the compounds have pharmacological activities of resisting influenza viruses, Coxsackie B3 viruses, AIDS viruses, hepatitis B viruses, hepatitis C viruses and the like. Therefore, the invention further provides the application of the compounds and the medicinal compositions containing the compounds serving as active ingredients in preparation of anti-virus medicaments. The invention lays a foundation for deeply researching and developing the application of the compounds as clinical medicaments. The general formula I is as shown in the specification.

CAJANINE STRUCTURE ANALOGOUS COMPOUND, PREPARATION METHOD AND USE

Provided are cajanine structure analogous compounds, synthesis method and pharmacological effects thereof, the compounds of the present invention having the structure as represented by general formulas I, II, III, IV and V. Also provided are pharmaceutical compositions containing the compounds as active ingredient, and uses thereof; the compounds of the present invention having the pharmacological activities such as anti-virus, anti-virus-infection, nerve protection, anti-metabolic-diseases and the like. Also provided is a chemical total synthesis preparation method of the natural products cajanine, cajanine A and cajanine C. The present invention lays a foundation for the in-depth study and development of the compounds as clinical drugs in the future.

CAJANINE STRUCTURE ANALOGOUS COMPOUND, PREPARATION METHOD AND USE

Provided are cajanine structure analogous compounds, synthesis method and pharmacological effects thereof, the compounds of the present invention having the structure as represented by general formulas I, II, III, IV and V. Also provided are pharmaceutical compositions containing the compounds as active ingredient, and uses thereof; the compounds of the present invention having the pharmacological activities such as anti-virus, anti-virus-infection, nerve protection, anti-metabolic-diseases and the like. Also provided is a chemical total synthesis preparation method of the natural products cajanine, cajanine A and cajanine C. The present invention lays a foundation for the in-depth study and development of the compounds as clinical drugs in the future.